Date: 2017-07-03
Type of information: Construction of new premises
Compound:
Company: Bayer Healthcare (Germany)
Therapeutic area: Veterinary medicine
Type agreement: construction of new premises
Action mechanism:
Disease:
Details:
- • On July 3, 2017, Bayer announced that until 2021, the company plans to invest around € 92 million into the further development of the production site in Kiel, where some of the most important products for the animal health global market are being manufactured. The goal is to strengthen particularly the growing business in the companion animal segment. Especially the rising demand for collars against fleas and ticks requires further investments into new production facilities and sophisticated filling and packaging lines. Another focus lies on expanding the production of pipettes with liquid parasite protection for pets. Other liquid products as well as an optimized production of pills for companion and farm animals will be supported with millions. In addition, Bayer will invest into stepping up the site’s infrastructure.
Financial terms:
Latest news:
Is general: Yes
